Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betrixaban - Alexion AstraZeneca Rare Disease

Next Previous
Drug Profile

Betrixaban - Alexion AstraZeneca Rare Disease

Alternative Names: Bevyxxa; Dexxience; MK-4448; MLN-1021; PRT 021; PRT 054021

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease; Portola Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Benzamides; Chlorinated hydrocarbons; Imines; Pyridines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Venous thromboembolism
  • Discontinued Stroke

Most Recent Events

  • 28 Apr 2021 No recent reports of development identified for phase-I development in Venous thromboembolism(In adolescents, In children, In infants, In neonates, Prevention) in Russia (PO, Capsule)
  • 16 Apr 2021 Discontinued - Preregistration for Venous thromboembolism (Prevention) in European Union (PO)
  • 10 Nov 2018 Interim sub-group analysis efficacy data from a phase III APEX trial in venous thromboembolism presented at the 91st Annual Scientific Sessions of the American Heart Association (AHA-2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top